Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mel-moe: Melatonin for sleep problems in children and adolescents with neurodevelopmental disorders
jRCTs071220104Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of melatonin in Sleep onset insomnia, Neurodevelopmental disorder (NDD), Autism Spectrum Disorder (ASD) and 5 more, sponsored by Nobelpharma Co., Ltd. Primary endpoint: Change in sleep onset latency. Started May 2023; status: completed.
02
Drugs
melatonin
03
Conditions
Sleep onset insomniaNeurodevelopmental disorder (NDD)Autism Spectrum Disorder (ASD)attention deficit hyperactivity disorder (ADHD)intellectual disability (ID)
Beyond the preview
Go deeper on jRCTs071220104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220104.